Home  »  Finance   »  Analysts suggest Exact Sciences Corporation (EXAS)...

Analysts suggest Exact Sciences Corporation (EXAS) could spike 31.26% in a year

Exact Sciences Corporation (NASDAQ: EXAS) is 31.89% higher on its value in year-to-date trading and has touched a low of $29.27 and a high of $84.31 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The EXAS stock was last observed hovering at around $67.82 in the last trading session, with the day’s loss setting it -2.52% off its average median price target of $62.00 for the next 12 months. It is also 31.26% off the consensus price target high of $95.00 offered by 21 analysts, but current levels are -86.57% lower than the price target low of $35.00 for the same period.

Currently trading at $65.30, the stock is 12.99% and 30.12% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.04 million and changing -3.72% at the moment leaves the stock 42.58% off its SMA200. EXAS registered -11.79% loss for a year compared to 6-month gain of 43.11%.

5 Undervalued Stocks For 2023

Approximately 544 miles north of Las Vegas lies what's been dubbed "the biggest lithium deposit in the US." One tiny company stands to be the biggest beneficiary because lithium "faces a long-term supply shortage," according to Barron's. This company, however, is sitting on a goldmine opportunity as it plans to produce 30,000 tonnes per annum over the next 3.5 years from this single deposit. Supplying the electric vehicle boom and potentially driving its stock price off the charts. But this is just one of the opportunities we have researched in our free report. The other four companies have just as much potential.

Click here to download your Free Copy…


The stock witnessed a 24.67% loss in the last 1 month and extending the period to 3 months gives it a 98.72%, and is -4.50% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.96% over the week and 5.44% over the month.

Exact Sciences Corporation (EXAS) has around 6420 employees, a market worth around $11.26B and $2.01B in sales. Profit margin for the company is -35.70%. Distance from 52-week low is 123.10% and -22.55% from its 52-week high. The company has generated returns on investments over the last 12 months (-10.90%).

Exact Sciences Corporation (EXAS) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Exact Sciences Corporation (EXAS) is a “Overweight”. 21 analysts offering their recommendations for the stock have an average rating of 1.70, where 6 rate it as a Hold and 1 think it is a “Overweight”. 14 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Exact Sciences Corporation is expected to release its quarterly report on 04/25/2023.The EPS is expected to grow by 36.20% this year.

Exact Sciences Corporation (EXAS) Top Institutional Holders

The shares outstanding are 177.00M, and float is at 176.12M with Short Float at 6.52%.

Exact Sciences Corporation (EXAS) Insider Activity

A total of 9 insider transactions have happened at Exact Sciences Corporation (EXAS) in the last six months, with sales accounting for 4 and purchases happening 5 times. The most recent transaction is an insider sale by Condella Sarah,the company’sEVP, Human Resources. SEC filings show that Condella Sarah sold 1,000 shares of the company’s common stock on Jan 09 at a price of $60.00 per share for a total of $60000.0. Following the sale, the insider now owns 85090.0 shares.

Exact Sciences Corporation disclosed in a document filed with the SEC on Oct 12 that Cunningham Everett (Chief Commercial Officer) sold a total of 16,872 shares of the company’s common stock. The trade occurred on Oct 12 and was made at $31.37 per share for $0.53 million. Following the transaction, the insider now directly holds 18654.0 shares of the EXAS stock.

Still, SEC filings show that on Aug 05, Baranick Brian (Gen. Mgr., Precision Oncology) disposed off 984 shares at an average price of $47.12 for $46366.0. The insider now directly holds 4,596 shares of Exact Sciences Corporation (EXAS).

Exact Sciences Corporation (EXAS): Who are the competitors?

The company’s main competitors (and peers) include Veracyte Inc. (VCYT) that is trading -4.04% down over the past 12 months and Invacare Corporation (IVC) that is -78.54% lower over the same period. Myriad Genetics Inc. (MYGN) is -20.96% down on the 1-year trading charts.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts